Related Experiment Video
Updated: Jun 21, 2026
06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
Clinical practice guidelines for severe Alzheimer's disease
Nathan Herrmann1, Serge Gauthier, Paul G Lysy
1Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. n.herrmann@utoronto.ca
Summary
Managing severe Alzheimer's disease (AD) requires comprehensive assessment and treatment strategies. Evidence-based guidelines can improve quality of life for patients and caregivers, but more research is needed.
Area of Science:
- Neurology
- Geriatrics
- Public Health
Background:
- Severe Alzheimer's disease (AD) is a significant public health concern with limited clinical management guidelines.
- The prevalence and cost of severe AD necessitate evidence-based approaches for effective patient and caregiver support.
Purpose of the Study:
- To review and synthesize existing evidence for managing severe Alzheimer's disease.
- To provide recommendations for clinical practice based on the best available scientific data.
Main Methods:
- Conducted a comprehensive literature search of English medical databases from 1996 to the present.
- Focused on studies involving patients with severe AD, assessing trial design, subjects, analysis, and results.
- Synthesized findings to develop evidence-based recommendations.
Main Results:
- Severe AD is reliably diagnosable using cognitive, functional, behavioral, and global staging measures.
- Management includes cholinesterase inhibitors/memantine for disease-specific treatment and non-pharmacologic approaches for neuropsychiatric symptoms.
- Atypical antipsychotics may treat dangerous agitation/aggression, with careful monitoring for risks like cerebrovascular events.
Conclusions:
- Evidence-based guidelines for severe AD management can enhance patient and caregiver quality of life.
- Urgent need for more randomized controlled trials focused on the severe stages of Alzheimer's disease.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.